Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 2 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 9 hours agoStrengths Robust mRNA Technology Platform: Moderna Inc (NASDAQ:MRNA) has established a strong...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 2 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 2 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 2 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 2 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 2 days ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 2 days agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 2 days agoModerna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 1 day agoThis downturn aligns with the expected transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna